Drug class
Human monoclonal antibody against Clostridioides difficile toxin B; recurrence-prevention biologic
Mechanism of action
Binds and neutralises C. difficile toxin B, preventing toxin-mediated cellular injury. Bezlotoxumab does not treat the active infection directly and is administered as an adjunct to antibacterial treatment to reduce recurrence risk.
General use cases
- Reduction of recurrence of Clostridioides difficile infection (CDI) in adults receiving antibacterial drug treatment for CDI who are at high risk of recurrence; not indicated as treatment for active CDI or as a substitute for antibacterial therapy
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
